Abstract-Cerebral autoregulation (CA) is a critical process for the maintenance of cerebral blood flow and oxygenation.
C erebral autoregulation (CA) adjusts cerebrovascular resistance to ensure that cerebral blood flow (CBF) levels are matched to metabolic needs; it is composed of 2 main components: static and dynamic. 1 "Static CA" regulates CBF over gradual and progressive changes in cerebral perfusion pressure, 2 whereas dynamic CA refers to the rapid regulation of CBF in response to changes in arterial blood pressure that occur across a few seconds (Ͻ5 s). 3 Assessment of CA is used as a critical tool for diagnosis, monitoring, or prognosis of cerebrovascular disease. The use of static and dynamic CA has been extensively validated to show that it is a highly sensitive and reliable index of a threatened cerebral circulation. 4 In 1959, Lassen 5 established that CBF in humans is independent of changes in mean arterial blood pressure (MAP) within a range of Ϸ60 to 150 mm Hg; and this has become the traditionally accepted model for static CA (as illustrated in Figure 1 ). However, this so-called autoregulatory curve relating CBF and MAP was based on steady-state CBF data points from a cohort of different subjects with and without pathology and included subjects premedicated with drugs now known to directly affect CBF regulation (as reviewed in Reference 4). Interestingly, Heistad and Kontos, 6 in 1983, performed a more accurate reanalysis of Lassen's 5 data by excluding some of these problematic groups. This reanalysis showed that CBF decreased 2% to 7% per 10-mm Hg fall in MAP and increased 7% per 10-mm Hg rise in MAP, challenging the notion that CBF is invariant to changes in MAP across the autoregulatory range. Unfortunately, this report, which is often overlooked in the literature, still deals with an ensemble of data taken from different subjects. Therefore, the CA curve remains to be clearly shown within healthy volunteers.
Impaired static CA, with loss of the more-or-less zeroslope MAP versus CBF relationship, has been reported in ischemic stroke, 7 in severe head injury, 8 after cardiac arrest, 9 and in patients with malignant hypertension. 10 Although the majority of these studies did not include a healthy age group for comparison, they indicated that CA was impaired because of the relatively high slope of the MAP versus CBF relationship. Moreover, in all studies, the confounding influence of arterial PCO 2 was not controlled for during blood pressure manipulations. Because changes in arterial PCO 2 have a profound independent effect on CBF, it not clear whether the changes in CBF were determined by the blood pressure, per se, or by concomitant changes in arterial PCO 2 . This is an important consideration because, at least during orthostatic hypotension, reductions in arterial PCO 2 of Ϸ8 mm Hg account for Ϸ25% of the reduction in CBF velocity. 11 Thus, despite the extensive use and reference to static CA, quantification of CA has not been clearly identified for human experimentation. In addition, near infrared spectroscopy (NIRS) for the monitoring of local cerebral oxygenation has been used in the clinical assessment of CA, 12 in addition to the assessment of cerebral ischemia. 13 The use of NIRS is attractive because it is noninvasive, does not require frequent calibration, is robust, and, unlike transcranial Doppler, the problem of a constant and precise location of the probes is less of an issue. Recently, Brassard et al 14 have published data on cerebral oxygenation responses using NIRS during norepinephrine-induced hypertension in healthy subjects. These authors reported that progressive increases in MAP resulted in elevations in cerebral oxygenation and reductions in CBF velocity. However, the use of norepinephrine to increase MAP confounds the hemodynamic responses in the cerebrovasculature, because it is a vasoactive agent that alters CBF independent of its effect on MAP. 15 Furthermore, because a decrease in arterial PCO 2 induces a 2% to 3% decline in CBF velocity per millimeter of mercury, 16 the observed decline in CBF velocity was also likely influenced by the reported decline in arterial PCO 2 . Therefore, the main aim of this current study, while controlling for the influence of arterial PCO 2 , was to provide the first clear examination of static CA in healthy humans over a wide range of blood pressures.
Methods

Subjects
Eleven healthy individuals (1 women, subject 1; Table) , age 27Ϯ7 years, height 179Ϯ9 cm, weight 73Ϯ8 kg (meanϮSD) were recruited to participate in the study, which was approved by the Central Regional Ethics Committee and conformed to the standards set by the Declaration of Helsinki. Subjects were informed of the experimental procedures and possible risks involved in the study, and written informed consent was obtained. Subjects were not taking any medication, all were nonsmokers, and none had any history of cardiovascular, cerebrovascular, or respiratory disease.
Perfusion Pressure (mm Hg) 60 150
Cerebral Blood Flow/MCAv CVR Figure 1 . Illustration of the traditionally viewed concept of cerebral autoregulation, either assessed using the Kety-Schmidt method 5 or transcranial Doppler ultrasound. 18 Typically, CBF or CBF velocity (ie, MCAv) is thought to be maintained constant (the so-called autoregulatory plateau) via changes in cerebrovascular resistance over a wide range of perfusion pressures.
Once the limits of autoregulation are reached, cerebrovascular resistance cannot correct for further changes in pressure, and the brain becomes "pressure passive," as represented by the linear portion of the curve Ͻ60 mm Hg (lower limit) or Ͼ150 mm Hg (upper limit). 
Experimental Design
After full familiarization (excluding cannulation) of each subject to the experimental protocol (Ͼ1 week previous), subjects arrived at the laboratory having abstained from caffeinated beverages for 12 hours and strenuous physical activity and alcohol for Ն24 hours before the day of the experiment.
Measurements of Arterial Blood Pressure, CBF Velocity, and Oxygenation
After local anesthesia (1% lidocaine), a 20-gauge catheter (BD Insyte) was placed into the radial artery and attached to a pressure transducer (Deltran II, Utah Medical Products Ltd) positioned at the level of the right atrium in the midaxillary line for the measurement of beat-to-beat arterial blood pressure. After cannulation, subjects rested quietly in the supine position, breathing room air, for Ն20 minutes to allow the setup of monitoring equipment, which included calibration of this pressure transducer. Blood flow velocity in the right middle cerebral artery was measured using a 2-MHz pulsed Doppler ultrasound system (DWL Doppler) using search and fixation techniques described elsewhere. 11, 17 The use of transcranial Doppler ultrasound for the noninvasive assessment of CBF during profound pharmacological-induced changes in MAP has been validated previously. 18 Beat-to-beat arterial blood pressure and heart rate were also monitored using finger photoplethysmography (Finometer, TPD Biomedical Instrumentation) and ECG, respectively. For comparison with earlier studies, 1,19 cerebrovascular resistance index (CVRi) was calculated from MAP and mean CBF velocity (MCAv; MCAv mean ) as CVRiϭMAP/MCAv mean . However, CVCi (flow/pressure) was also calculated as CVCiϭMCAv mean /MAP, because this index better reflects regional vascular tone under situations where changes in tone lead to changes in flow. 20 As used previously, 11,21 the Gosling pulsatility index for MCAv was calculated by: MCAv systolic Ϫ MCAv diastolic /MCAv mean . Frontal cortical oxygenation was monitored noninvasively on the right side of the forehead using NIRS (NIRO-200, Hamamatsu Photonics KK). For details on this measure, please see the online Data Supplement (available at http://hyper. ahajournals.org). All of the data were acquired continuously at 200 Hz using an analog-to-digital converter (Powerlab/16SP ML795, ADInstruments) interfaced with a computer and were subsequently analyzed using commercially available software (Chart version 5.6, ADInstruments).
Measurements and Control of Respiratory Gas Exchange
Subjects were instructed to breathe at the same rate and depth during the drug infusions, and, if needed, to adjust their baseline tidal volume level to maintain end-tidal PCO 2 close to baseline level. For details on this measure, please see the online Data Supplement.
Pharmacological-Induced Alterations in MAP
Steady-state testing of CA was achieved by stepwise lowering and increasing of MAP in Ϸ10-mm Hg increments via intravenous infusion of sodium nitroprusside and phenylephrine hydrochloride (for details on this measure please see the online Data Supplement). Each step was held relatively constant for 30 to 90 s. The drug order was randomly assigned, and subjects rested for Ͼ10 minutes between drug interventions to ensure adequate washout and return to baseline MAP. Throughout the test protocol, the online intra-arterial blood pressure and ECG waveform morphology were closely monitored. Studies were terminated if cardiac effects associated with either drug infusion were identified on the ECG or if subjects developed symptoms or signs of intolerance. Therefore, although we aimed for 6 to 7 steps of pressure change, either side of baseline within each subject, this was not achieved in all of the individuals.
Calculations
Static CA was calculated using linear regression to calculate the slope, correlation coefficient (r) and determination (R 2 ), and significance value between MCAv and MAP. 22 With this method, if the slope is Ϸ0, it can be assumed that the linear regression coincides with the plateau region of a normal autoregulatory curve. If the slope is significantly positive, this can either represent the linear portion of the curve below its lower limit (Figure 1) or the central region of the curve when autoregulation is impaired (eg, Ͼ0.5% to 3.0% increase in MCAv per millimeter of mercury change in MAP 4 or when rϾ0.5 23 ).
Statistical Analysis
Data were analyzed using SPSS (version 15, SPSS Inc). A repeatedmeasures design was used with changes in dependent variables compared with the preceding baseline. To enable comparisons with other studies and to reduce interindividual variability unrelated to the experimental manipulation, 11, 21, 24 dependent variables were expressed as a change from baseline in both absolute and relative terms. Dependent variables of interest were analyzed as a linear function of change in MAP, with comparison of slopes between hypotension and hypertension undertaken using a paired-sample t test. Average change in MCAv and CVR within each 10-mm Hg step in MAP from baseline was used to show the average group changes for these dependent variables across the range of MAP (Figure 2 ). Pearson correlations were used to examine the relationships between the change in MAP with MCAv mean and cortical oxygenation for each subject (Table) . For the pooled data, within-subject correlation coefficients using a multiple regression were used to examine the change in MAP with MCAv mean and cortical oxygenation, using the method described by Bland and Altman 25 ( Figure 3) . All of the group data are expressed as meanϮSD. Significance was established at an ␣ level of PϽ0.05.
Results
On average, although tidal volume and breathing frequency were maintained, MCAv mean changed 0.82Ϯ0.35% per millimeter of mercury change in MAP (Table) . There was no difference between the slopes for hypotension and hypertension for MCAv mean versus MAP and cortical oxygenation versus MAP (all PϾ0.05); therefore, these data were pooled across the range of MAP for each subject (Table) . On the basis of the pooled group data (117 measurement points, excluding baselines), the relative changes in MCAv mean , CVRi, and CVCi are illustrated in Figure 2 . Compared with baseline, the relative and absolute change in MCAv mean were positively related (slopeϭ0.82% ⅐ mm Hg Ϫ1 , R 2 ϭ0.82 and slopeϭ0.55 cm ⅐ s Ϫ1 ⅐ mm Hg Ϫ1 , R 2 ϭ0.77, respectively) to the change in MAP (both PϽ0.01; Figure 3B ). Changes in cortical oxygenation were inversely related to changes in MAP (slopeϭϪ0.18% ⅐ mm Hg Ϫ1 ; R 2 ϭ0.60; Figure 3A ) and MCAv mean (slopeϭϪ0.26%/cm ⅐ s Ϫ1 ; R 2 ϭ0.54; Figure 3C ). Hypotension caused a larger fall in MCAv diastolic than in MCAv systolic , whereas during hypertension they increased similarly ( Figure 2A ); these differences are reflected by the differential MCAv pulsatility responses between hypotension and hypertension ( Figure 2C ).
Discussion
This is the first study to report the systemic changes in MCAv and cerebral oxygenation over a wide range of pharmacologically induced alterations in MAP in otherwise healthy humans. The major new findings are as follows: (1) there is a relative "pressure-passive" relationship in otherwise healthy humans during pharmacological-induced changes in MAP; (2) progressive hypotension and hypertension were associated with differential changes in cerebral oxygenation and MCAv mean ; and (3) during hypotension, but not hypertension, despite a preferential decrease in MCAv diastolic , MCAv systolic was well maintained, that is, pulsatility of MCAv was elevated. Collectively, our findings indicate that CBF and oxygenation are not independent of changes in blood pressure; therefore, a paradigm shift in the concept of CA is required. Before we discuss the theoretical and physiological implications of our findings, several methodological aspects of the study require comment. 
Methodological Considerations
There are 2 main technological considerations that merit clarification. First, changes in MCAv reflect changes in flow, 26 provided MCA diameter remains constant; therefore, an important consideration is whether the pharmacological agents used to manipulate MAP could interfere with the CA adjustments via direct vasodilatory (ie, sodium nitroprusside) or vasoconstrictive (ie, phenylephrine) effects on the MCA or cerebral resistance vessels. Direct observations made during craniotomy have revealed that sodium nitroprusside does not affect the vessel diameter of the MCA. 27 In addition, constancy of MCA diameter has been demonstrated for a range of blood pressures. 28 Both human 29 and animal 30 studies indicate that phenylephrine has no relevant vasoconstriction of cerebral vasculature. Furthermore, intravenous infusion of phenylephrine increases arterial pressure acutely but is unlikely to have a direct effect on the cerebral blood vessels, because it does not pass the blood-brain barrier, and the density of ␣ 1 -adrenorecepors in the cerebral blood vessels is likely to be low in humans. 29, 31 It is acknowledged that a disruption of the blood-brain barrier can occur with hypertension. However, the evidence for this is largely from animal studies that have induced extreme levels of hypertension (eg, MAP Ͼ180 mm Hg 32 ) that scarcely resemble the conditions of this study. Admittedly, a change in the vascular resistance of the smaller arterioles in the cerebral vasculature may have occurred during our drug infusions; however, any effect of sodium nitroprusside on downstream (distal) vascular resistance should be one of augmenting CBF, not inhibiting it. Likewise, any ␣ agonist activity with phenylephrine would reduce CBF rather than increase it. Therefore, in the current study, we consider that changes in MCAv were proportional to those in blood flow; any direct effect of sodium nitroprusside or phenylephrine on downstream vascular resistance would actually favor the plateau phenomenon of CA rather than the pressure-passive relationship observed in the current study. Second, the advantages and limitations of NIRS have been well described 33, 34 and validated against multiple experimental and imaging modalities. [35] [36] [37] [38] [39] 
Comparison With Previous Studies
The origin of the autoregulation curve is usually attributed to Lassen 5 and further emphasized in a detailed review by Paulson et al 2 in 1990. What is not commonly appreciated is that Lassen 5 plotted the results from multiple studies on a single graph and interpolated the data points to show a plateau region that appeared perfectly flat, suggesting that CBF was held constant for changes in MAP in the range Ϸ60 to 150 mm Hg. Collectively, these 2 studies have been cited Ͼ1500 times, with Lassen's review 5 cited Ϸ1000 times alone. However, this so-called autoregulatory curve between CBF and MAP was based on steady-state CBF data points from a cohort of different subjects with and without pathology and included subjects premedicated with drugs now known to directly affect CBF regulation (as reviewed in Reference 4). An important, yet often overlooked, reanalysis of the data presented by Lassen 5 was published by Heistad and Kontos 6 in 1983, which, with the exclusion of some of these problematic groups, reported a 2% to 7% decrease in CBF per 10-mm Hg fall in MAP and a 7% increase in CBF per 10-mm Hg rise in MAP. Even so, the diagrammatic representation that these authors use to illustrate the relationship between CBF and perfusion pressure still shows a plateaulike portion in the curve, 6 and, surprisingly, Heistad in a later publication 40 suggested that, "CBF is regulated at or near control levels over a wide range of systemic pressure" (p 10). In comparison, our data indicate that MCAv mean (as a surrogate for CBF) changed Ϸ8% per 10-mm Hg change in MAP across both hypotension and hypertension. Therefore, our findings indicate an even more marked positive slope of the MAP-CBF relationship, using dynamic measurement technology (ie, transcranial Doppler) compared with that described by Heistad and Kontos 6 from studies using the classic steady state Kety-Schmidt method, 15, [41] [42] [43] and, importantly, for the first time, this was observed within the same individuals. It should also be noted that these previous studies did not provide information on the serial changes in CBF over a wide range of blood pressure and did not control for the confounding influence of PaCO 2 . At least during orthostaticinduced hypotension, reductions in arterial PCO 2 of Ϸ8 mm Hg account for Ϸ25% of the reduction in CBF velocity 11 ; therefore, if comparable changes occurred during the pharmacological-induced hypotension, it is conceivable that our findings are an underestimation of what would occur during uncontrolled, nonexperimental situations. Thus, this is further evidence that the plateau region of the CA curve is not valid for healthy subjects. The concept that the plateau region has a slope of zero has had considerable influence on the static assessment of CA in physiological and clinical studies. Our findings clearly show that, at least in healthy humans, the slope between CBF and MAP is relatively linear (Table; compare Figure 1 with Figure 2 ). This finding is consistent with the view shared by a number of authors 6, 22 who are also cognizant of the limitations of Lassen's 5 original analysis. Moreover, consistent with our findings, mathematical models also indicate that perfect CA (ie, flat plateau) would require feedback gains much greater than those normally observed in biological systems. 44, 45 Our data provide evidence that a finite slope of the plateau region does not necessarily imply defective autoregulation.
We found that the degree of relative change in MCAv mean after change in MAP is 0.82% per millimeter of mercury change in MAP. The key question arises: how do these changes compare with those reported in pathological studies, which are suggested to represent "impairment" in CA? Previously, using transcranial Doppler, values between 0.5% and 3.0% per millimeter of mercury change in MAP have been proposed as thresholds for an impaired autoregulation (reviewed in Reference 4). More recently, in patients with malignant hypertension, the slope of reduction in MCAv with MAP was shown to be smaller with labetalol than with sodium nitroprusside (0.45% versus 0.78% cm ⅐ s Ϫ1 ⅐ mm Hg
Ϫ1
). 46 Unfortunately, data for a control group were not reported. Impaired CA, with loss of the more-or-less zero-slope MAP-MCAv relationship, has also been reported in ischemic stroke, 7 in severe head injury, 8 after cardiac arrest, 9 and in patients with malignant hypertension. 10 The same comparison exists with investigators performing linear regression analysis, adopting the correlation coefficient (r) as a measure of CA. 23, 47 Although the majority of these studies did not include a healthy age group for comparison, they nevertheless concluded that CA was impaired because of the relatively high correlation coefficient of the MAP versus CBF relationship. The findings of the present study, on the basis of otherwise healthy humans, indicate that neither a high linear regression slope nor a correlation coefficient between alterations in CBF with MAP necessarily imply a defective CA.
The data in the Table illustrate the presence of betweenindividual variability for the CA response in our healthy participants. Maintenance of adequate cerebral perfusion during normal physiological challenges, such as assumption of upright posture from a supine, squatting, or sitting position, requires the integrated control of CBF and systemic blood pressure via CA and the arterial baroreflex. 48 In our experimental design, we effectively override the input from one of these components (ie, the baroreflex) by pharmacologically maintaining an increased or decreased MAP. Although speculative, it would seem possible that some of the variation in the CA response between participants could be explained by between-individual variability in the CA-baroreflex relationship; that is, those with a greater input from the baroreflex under "normal conditions" would show the greater reductions in CA in this experimental setting. Our future work is aimed at examining the fundamental relationships between baroreflex and CA.
Regional Differences in MCAv and Cerebral Oxygenation
An unexpected finding was that, whereas MCAv mean was progressively reduced with hypotension, cerebral oxygenation was elevated ( Figure 3C ). Our correlative (R 2 ) data identify that the relationship between cerebral oxygenation and MAP explains 60% of the variance and that between cerebral oxygenation and MCAv mean explains 54% of the variance. With hypertension, the opposite response occurred; that is, the elevations in MAP were associated with marked elevations in MCAv mean and significant reduction in cortical oxygenation ( Figure 3A and 3B ). Moreover, with progressive hypertension, the relationship between MCAv mean and cerebral oxygenation appears reduced ( Figure 3C) . The extent to which these findings are explained by the pressure and flow-sensitive changes of simple extracranial-intracranial collaterals or changes in sympathetic nerve activity distal to the MCA warrants future study. Regardless of the mechanism(s), which cannot be determined from our data, the reduction in cerebral oxygenation during hypertension is particular noteworthy, because it was reduced by Ϸ14% during the higher range of MAP ( Figure 3A) ; this reduction approximates the Ϸ13% estimated in a recent study as the "threshold" for cerebral ischemia. 13 The clinical relevance of these findings is that, with progressive hypertension, there may be a selective risk of severe cerebral ischemia to the intracranial regions over that of the extracranial regions, especially in those where CBF might already be compromised (eg, carotid artery stenosis and aortic stenosis). The possibility that discreet regions of the brain may respond differently during hypertension, to an extent of local ischemia, warrants further confirmation with functional magnetic resonance that also measures the balance between deoxyhemoglobin and oxyhemoglobin to evaluate the regional distribution of CBF and oxygenation. As mentioned, because NIRS is noninvasive, does not require frequent calibration, is robust, and avoids the issues of probe movement, the advantage for using NIRS for clinical monitoring, including assessment of CA, 12 is potentially immense. However, on the basis of the findings of the current study, it would seem necessary to express caution in using NIRS to monitor CA, because it likely reflects very different alterations in cerebral perfusion.
Static Versus Dynamic CA
Static measurements evaluate the overall efficiency of the autoregulatory action, that is, the change in CVR in response to the manipulation of MAP, but they do not address the time in which this change in CVR is achieved (ie, its "latency"). Nevertheless, a close relationship has been reported between both dynamic and static measurements of CA. 1 More recently, an elegant study has identified that changes in CVR due to steady-state (static) CA modulate the dynamic pressure-flow relationship of the cerebral circulation. 19 Despite observing a similar pattern for the CVR responses to that seen in the current study ( Figure 2B ), Zhang et al 19 did not observe the same change in CBF with 3 of the 4 steady-state increases in MAP. Nevertheless, their final pharmacologically induced elevation in MAP, which was within the so-called autoregulatory "plateau" (112 mm Hg), was associated with an increase in CBF. Therefore, Zhang et al 19 findings lend additional support to our observations of a pressure-passive regulation of CBF.
Differential Changes in CBF Velocity Pulsatility During Hypotension
A relevant and novel observation in the present study was that, during hypotension but not hypertension, despite a preferential decrease in MCAv diastolic , MCAv systolic was relatively well maintained, that is, pulsatility of MCAv was elevated ( Figure 2C ). Although the etiology of the differential changes in pulsatility with hypotension are not known, elevations in pulsatility have been interpreted as a compensatory response that is associated with CBF preservation despite falling perfusion pressure by promoting pulsatile flow. 49 It has also been suggested, at least in patients with head injury, that pulsatile flow requires less energy expenditure to maintain forward flow. 47 At least in the animal model, this compensatory mechanism maintains CBF until further dilation and fall in MCAv diastolic is exhausted; once that point is surpassed, CBF diminishes rapidly. 49 The preferential declines in MCAv diastolic and maintained MCAv systolic are consistent with the changes that occur during profound hypotension at the point of syncope. 11, 50 Some consider this increase in MCAv pulsatility to be indicative of a paradoxical increase in cerebrovascular resistance before syncope. 21, 24 Others note that MCAv mean decreases much less than does MAP, implying that dynamic cerebral autoregulatory mechanisms are intact and functioning at syncope. 50 
Perspectives
The concept that the plateau region has a slope of 0 has had considerable influence on the static assessment of CA in physiological and pathophysiological investigations. Routine evaluation of CA in health and disease requires objective and reliable indices that can provide a continuous measure of vasomotor control of CBF in the presence of fluctuations in MAP. Although both the slope and linear regression indices are well-established parameters for this purpose, previous studies have not adequately considered what constitutes the normal response. Such studies have incorrectly assumed that the plateau response is a robust experimentally tested observation. Our data clearly show that, in healthy humans, the normal slope between CBF and MAP is relatively linear. The 2 major implications of our findings are that, in contrast to the innumerable reports in the literature, a finite slope of the plateau region does not necessarily imply a defective CA, and CBF and oxygenation are not independent of changes in blood pressure; therefore, a paradigm shift in the concept of CA is required. 
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